Bilastine,a newly registered H1-antihistamine,can be orally administrated to treat allergic rhinitis and urticaria.The absorption of bilastine is fast,but it slows when taken with food or fruit juice.Data have confirmed that bilastine has a higher affinity for H1 histamine receptors than for the other receptors,and can reduce the levels of histamine and cytokines.For histamine-induced cutaneous wheal and flare reactions,bilastine 20 mg shows equivalent inhibitory effect with a probably faster onset of action compared with cetirizine 10 mg.With no anticholinergic effect,bilastine dose not impair driving ability.In addition,bilastine has a good tolerability profile with no sedative side effects,no cardiac toxicity,and no hepatic toxicity,which will make it have a broader prospect for clinical application in the future.